Back to Search
Start Over
Iloprost for idiopathic pulmonary arterial hypertension
- Source :
- Expert Review of Cardiovascular Therapy. 3:215-223
- Publication Year :
- 2005
- Publisher :
- Informa UK Limited, 2005.
-
Abstract
- Idiopathic pulmonary arterial hypertension is a rare but serious and life-threatening disease that leads to right heart failure and death within 2.8 years without specific treatment. This review focuses on the stable prostacyclin analog iloprost, its biologic action and pharmacology and, finally, on its clinical development, efficacy and safety in patients with idiopathic pulmonary arterial hypertension, which led to its approval for this indication. Furthermore, this review assesses the role of iloprost compared with other newly developed drugs, such as the endothelin receptor antagonist bosentan and the phosphodiesterase-5 inhibitor sildenafil, as well as other modes of application of prostacyclin and its analogs for the treatment of idiopathic pulmonary arterial hypertension. Based on the different modes of action of these substances, a combination of these treatments could be most promising for the future.
- Subjects :
- medicine.medical_specialty
Sildenafil
Hypertension, Pulmonary
Vasodilator Agents
Prostacyclin
Disease
chemistry.chemical_compound
Internal medicine
Internal Medicine
medicine
Humans
Iloprost
Clinical Trials as Topic
business.industry
Endothelin receptor antagonist
Idiopathic Pulmonary Arterial Hypertension
General Medicine
medicine.disease
Pulmonary hypertension
Bosentan
chemistry
cardiovascular system
Cardiology
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 17448344 and 14779072
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Expert Review of Cardiovascular Therapy
- Accession number :
- edsair.doi.dedup.....ff28a3bfc6e28897b3ba3df9af97858c